-
FDA rushes J&J, NewLink Genetics Ebola vaccines to clinical trials
Another Big Pharma player is joining the hustle toward an Ebola vaccine as the death toll surpasses 1,900 victims, eclipsing the total number of people who died from the disease in all previous outbreaks combined.
- Categories
- Health Care
- Region
- Sub-Saharan Africa
-
Final trial confirms efficacy of Sanofi’s dengue vaccine
French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros ($1.7 billion) in the project, undertaking two decades of research on the world's fastest-growing tropical disease.
- Categories
- Health Care
- Tags
- vaccines
-
Ebola: Can Global Health Be Sustainably Promoted Without A Framework Convention for Global Health?
Few events remind us more of humanity’s shared health vulnerability than the outbreak of an untreatable, highly lethal disease that is resisting efforts to contain it, spreading from community to community, and across borders from country to country – like the current Ebola outbreak in West Africa.
- Categories
- Health Care
- Region
- Sub-Saharan Africa
-
Global health officials warn that window for bringing Ebola under control is closing fast
Leading international health officials said Tuesday that the Ebola epidemic in West Africa is accelerating and the window for getting it under control is closing.
- Categories
- Health Care
- Region
- Sub-Saharan Africa
-
Ebola outbreak could infect 20,000 people, WHO says
The Ebola epidemic in West Africa could infect over 20,000 people and spread to more countries, the U.N. health agency said on Thursday, warning that an international effort costing almost half a billion dollars is needed to overcome the outbreak.
- Categories
- Health Care
- Region
- Sub-Saharan Africa
-
GSK Announces Commitment to Improving Access to Vaccines With 5-year Price Freeze
GlaxoSmithKline (GSK) has announced that it will freeze the prices of its vaccines for five years for developing countries that graduate from GAVI Alliance support. By committing to offer GAVI Alliance prices for vaccines against pneumonia, diarrhoea and cervical cancer, GSK will support developing country governments as they transition to financing the full cost of their local vaccination programmes.
- Categories
- Health Care
- Region
- Sub-Saharan Africa
-
How to Prevent the Next Health Crisis: Without vaccines, we’re vulnerable not just to Ebola, but a variety of other deadly diseases
More than 20 million kids weren’t vaccinated last year. How do we fix that problem? Dr. Utibe Effiong says we can start by engaging with more religious leaders to encourage vaccination. More importantly, we must invest in job creation to bring families out of poverty. When a family is hungry, vaccination is their last priority.
- Categories
- Health Care
-
Global Health Investment Fund Leads Investment into Low-Cost Oral Cholera Vaccine for the World’s Poor
South Korean biopharmaceutical company commits to manufacture a new and improved presentation of the vaccine at a target price of $1.00 per dose for public sector buyers.
- Categories
- Health Care
Subscribe to Our 'Business in Global Development' Newsletter!
Our new weekly LinkedIn newsletter features NextBillion's latest original articles, along with curated news, jobs, bizdev opportunities and events from our recent coverage of impact-focused business in emerging markets.
We respect your privacy. Your information is safe and will never be shared.
Don't miss out. Subscribe today.